Drug Trial Radar · NCT05775523
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 20, 2023
Primary completion
Mar 2033
Study completion Mar 2033
Sponsor
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/SIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Conditions
- Growth Hormone Deficiency
Interventions
No interventionDrug
No intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of neoplasms (benign, malignant and unspecified)Time frame: 5 years
- Occurrence of type 2 diabetes mellitusTime frame: 5 years
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Ascendis Investigational Site
Phoenix, Arizona · Recruiting
Ascendis Investigational Site
Orange, California · Recruiting
Ascendis Investigational Site
Sacramento, California · Recruiting
Ascendis Investigational Site
San Francisco, California · Recruiting
Ascendis Pharma Investigational Site
Centennial, Colorado · Recruiting
Ascendis Investigational Site
Washington D.C., District of Columbia · Recruiting
Ascendis Investigational Site
Orlando, Florida · Recruiting
Ascendis Investigational Site
Orlando, Florida · Recruiting
Ascendis Investigational Site
Tampa, Florida · Recruiting
Ascendis Investigational Site
Sandy Springs, Georgia · Recruiting
Ascendis Investigational Site
Boise, Idaho · Recruiting
Ascendis Investigational Site
Indianapolis, Indiana · Recruiting
Ascendis Investigational Site
Iowa City, Iowa · Recruiting
Ascendis Investigational Site
Louisville, Kentucky · Recruiting
Ascendis Investigational Site
Minneapolis, Minnesota · Recruiting
Ascendis Investigational Site
Las Vegas, Nevada · Recruiting
Ascendis Investigational Site
Lebanon, New Hampshire · Recruiting
Ascendis Investigational Site
Manchester, New Hampshire · Recruiting
Ascendis Investigational Site
Morristown, New Jersey · Recruiting
Ascendis Investigational Site
New Hyde Park, New York · Recruiting
Ascendis Investigational Site
Cincinnati, Ohio · Recruiting
Ascendis Investigational Site
Portland, Oregon · Recruiting
Ascendis Investigational Site
Columbia, South Carolina · Recruiting
Ascendis Investigational Site
Dallas, Texas · Recruiting
Ascendis Investigational Site
El Paso, Texas · Recruiting
Ascendis Investigational Site
Norfolk, Virginia · Recruiting
Ascendis Investigational Site
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.